CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 42,243 shares, an increase of 324.4% from the August 15th total of 9,954 shares. Based on an average daily volume of 141,321 shares, the short-interest ratio is presently 0.3 days. Currently, 5.8% of the company’s shares are short sold.

CDT Equity Stock Performance

CDT opened at $0.25 on Friday. CDT Equity has a 52-week low of $0.23 and a 52-week high of $2,360.00. The stock has a market capitalization of $196,750.00, a PE ratio of -0.00 and a beta of 1.48. The stock’s 50 day moving average price is $2.67 and its 200-day moving average price is $36.07.

CDT Equity (NASDAQ:CDT) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($8.71) EPS for the quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on CDT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday, June 24th. Wall Street Zen raised shares of CDT Equity from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.